Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

tVNS in Long COVID-19

NCT: NCT06585254 · ACTIVE_NOT_RECRUITING

NCT IDNCT06585254
StatusACTIVE_NOT_RECRUITING
Start Date2024-11-01
Completion2027-02-01
SponsorIcahn School of Medicine at Mount Sinai (OTHER)
First posted
Last updated

Brief Summary

A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). The purpose of this study is to compare two sets of stimulus parameters to determine the one that best improves the health-related quality of life of these patients over a period of 6-weeks. Patients using their assigned device for at least 30 of the 42 possible opportunities will receive the best device for an additional 6-week period.

Frequently Asked Questions

What is tVNS in Long COVID-19?

tVNS in Long COVID-19 is a clinical trial registered under NCT06585254. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06585254?

The current status of NCT06585254 (tVNS in Long COVID-19) is: ACTIVE_NOT_RECRUITING.

When did tVNS in Long COVID-19 start?

tVNS in Long COVID-19 started on 2024-11-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.